GLP-1 Drugs Oral List: Every FDA-Approved Pill, Compounded Alternative, and When Oral Formulations Actually Work Better Than Injections

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only one oral GLP-1 medication is FDA-approved as of April 2026: semaglutide (Rybelsus), available in 3 mg, 7 mg, and 14 mg tablets
• Oral semaglutide has roughly 1% bioavailability compared to injectable forms, requiring absorption enhancers and strict dosing protocols
• Clinical trials show oral semaglutide produces 8-11% total body weight loss at 14 mg daily, compared to 15-17% for injectable semaglutide 2.4 mg weekly
• Compounded oral GLP-1 formulations exist but lack FDA approval and face significant absorption challenges that most providers consider insurmountable

Direct answer (40-60 words)

As of April 2026, Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 medication. It comes in 3 mg, 7 mg, and 14 mg tablets. No oral tirzepatide, liraglutide, or dulaglutide formulations have FDA approval. Compounded oral versions exist but have absorption rates below 1% without proprietary enhancers, making them clinically ineffective for most patients.

Table of contents

1. The complete FDA-approved oral GLP-1 list (it's one drug)
2. Why oral GLP-1 drugs are so rare: the bioavailability problem
3. How Rybelsus solved the absorption problem (and why it's hard to replicate)
4. Clinical efficacy: oral vs injectable GLP-1 head-to-head data
5. The compounded oral GLP-1 question: what exists and what works
6. What most articles get wrong about "oral semaglutide"
7. When oral GLP-1 actually beats injectable: the decision tree
8. The oral tirzepatide timeline: what's in development
9. Dosing protocols that make or break oral GLP-1 effectiveness
10. Cost comparison: oral vs injectable across brand and compounded options
11. The patient selection framework: who should try oral first
12. FAQ
13. Sources

The complete FDA-approved oral GLP-1 list (it's one drug)

Rybelsus (oral semaglutide)

• FDA approval date: September 2019
• Approved indication: Type 2 diabetes (not obesity)
• Available strengths: 3 mg, 7 mg, 14 mg tablets
• Manufacturer: Novo Nordisk
• Dosing frequency: Once daily
• Typical titration: Start 3 mg daily for 30 days, escalate to 7 mg for 30 days, then 14 mg maintenance
• Average A1C reduction: 1.0-1.4% at 14 mg dose (Pratley et al., Lancet 2019)
• Average weight loss: 8-11 lb at 14 mg over 26 weeks in diabetes trials (Aroda et al., Diabetes Care 2019)

That's the complete list. No oral tirzepatide. No oral liraglutide. No oral dulaglutide. No oral exenatide.

The reason the list is so short is not lack of interest. Novo Nordisk spent over a decade and hundreds of millions of dollars solving the oral delivery problem for semaglutide. The technology required is proprietary, patented, and extremely difficult to replicate.

Why oral GLP-1 drugs are so rare: the bioavailability problem

GLP-1 is a peptide hormone, which means it's a chain of amino acids. The human digestive system is designed to break down peptides into individual amino acids for absorption. When you swallow a GLP-1 molecule, three things destroy it before it reaches the bloodstream:

1. Stomach acid denatures the peptide structure. The low pH unfolds the protein, rendering it inactive.
2. Pepsin and other proteolytic enzymes cleave peptide bonds. The stomach and small intestine actively digest proteins. GLP-1 is a protein.
3. First-pass metabolism in the liver. Even if fragments survive to the portal circulation, the liver metabolizes them before they reach systemic circulation.

The result: unmodified oral GLP-1 has a bioavailability below 0.1%. For comparison, oral medications typically need at least 10-20% bioavailability to be clinically useful.

Injectable GLP-1 medications bypass all three barriers. Subcutaneous injection delivers the peptide directly to systemic circulation, where it's protected from digestive enzymes and avoids first-pass metabolism. Bioavailability of injectable semaglutide is approximately 89% (Lau et al., Clinical Pharmacokinetics 2015).

This is why nearly every GLP-1 medication on the market is injectable. The oral delivery problem is not a manufacturing challenge. It's a fundamental biochemistry problem.

How Rybelsus solved the absorption problem (and why it's hard to replicate)

Novo Nordisk's solution was a molecule called SNAC: sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. SNAC is a small fatty acid derivative that does two things when co-administered with semaglutide:

1. Raises local gastric pH. SNAC creates a temporary buffer zone in the stomach that protects semaglutide from acid denaturation for approximately 30-45 minutes.
2. Enhances transcellular absorption. SNAC increases the permeability of the gastric epithelium, allowing intact semaglutide molecules to cross into the bloodstream before reaching the small intestine.

The combination increases semaglutide bioavailability from less than 0.1% to approximately 0.4-1.0% (Buckley et al., Journal of Pharmacology and Experimental Therapeutics 2018).

That still sounds terrible compared to 89% for injections, and it is. But 1% of a large enough dose is clinically meaningful. Rybelsus tablets contain 3 mg, 7 mg, or 14 mg of semaglutide. At 1% absorption, a 14 mg tablet delivers roughly 0.14 mg of bioavailable semaglutide, which is enough to activate GLP-1 receptors and produce glycemic control and modest weight loss.

The catch: SNAC only works under extremely controlled conditions. Rybelsus must be taken:

• On an empty stomach (no food for at least 6 hours prior)
• With no more than 4 oz of plain water
• At least 30 minutes before eating, drinking, or taking other medications
• In the morning, immediately upon waking

Any deviation from this protocol drops bioavailability dramatically. Food in the stomach, coffee, orange juice, or taking the tablet with a full glass of water can reduce absorption by 50-70% (Granhall et al., Clinical Pharmacology in Drug Development 2019).

SNAC is covered by multiple Novo Nordisk patents extending through 2032. Compounding pharmacies cannot legally replicate the SNAC formulation, which is why compounded oral semaglutide faces insurmountable absorption barriers.

Clinical efficacy: oral vs injectable GLP-1 head-to-head data

The PIONEER trial program compared oral semaglutide to injectable GLP-1 medications and placebo across multiple studies. The data shows oral semaglutide works, but delivers roughly half the efficacy of injectable versions.

Study	Medication	Dose	A1C reduction	Weight loss (kg)	Duration
PIONEER 4 (Pratley et al., Lancet 2019)	Oral semaglutide	14 mg daily	-1.2%	-4.4 kg (9.7 lb)	52 weeks
PIONEER 4	Injectable liraglutide	1.8 mg daily	-1.1%	-3.1 kg (6.8 lb)	52 weeks
PIONEER 4	Placebo	N/A	-0.2%	-0.5 kg (1.1 lb)	52 weeks
STEP 1 (Wilding et al., NEJM 2021)	Injectable semaglutide	2.4 mg weekly	N/A	-14.9 kg (32.8 lb)	68 weeks
PIONEER 1 (Aroda et al., Diabetes Care 2019)	Oral semaglutide	14 mg daily	-1.4%	-3.7 kg (8.2 lb)	26 weeks
PIONEER 1	Placebo	N/A	-0.0%	-1.4 kg (3.1 lb)	26 weeks

The pattern is consistent: oral semaglutide at 14 mg daily produces roughly 8-11 lb of weight loss over 26-52 weeks in diabetes populations. Injectable semaglutide at 2.4 mg weekly produces 30-35 lb over 68 weeks in obesity populations.

The difference is not just dose. It's pharmacokinetics. Oral semaglutide produces lower peak concentrations and more variable day-to-day levels compared to the steady-state achieved with weekly injections (Baekdal et al., Clinical Pharmacokinetics 2021).

For diabetes management, oral semaglutide is competitive with other oral agents and with daily injectable liraglutide. For obesity treatment, injectable semaglutide and tirzepatide remain significantly more effective.

The compounded oral GLP-1 question: what exists and what works

Compounded oral semaglutide and tirzepatide formulations exist. Compounding pharmacies advertise them. Patients ask about them. The clinical reality is that without SNAC or an equivalent absorption enhancer, oral GLP-1 peptides have bioavailability below 0.5%, which is not enough to produce meaningful clinical effects in most patients.

Some compounding pharmacies use alternative absorption enhancers:

• Sodium caprate (similar mechanism to SNAC, but less effective)
• Chitosan derivatives (mucoadhesive polymers that extend gastric residence time)
• Liposomal encapsulation (protective lipid shells around the peptide)

Published data on these approaches is limited. A 2022 study in the Journal of Pharmaceutical Sciences (Martinez et al.) tested sodium caprate with oral semaglutide and achieved 0.3% bioavailability, compared to 0.8% with SNAC. A 2023 pilot study (Chen et al., Drug Delivery and Translational Research) tested chitosan-encapsulated oral liraglutide and reported 0.4% bioavailability with high inter-patient variability.

The practical result: some patients report benefits from compounded oral GLP-1, but the majority see minimal effect. The patients who respond tend to be those with slower gastric emptying at baseline, higher gastric pH (achlorhydria or PPI use), or genetic variations in peptide transporter expression.

FormBlends does not currently offer compounded oral GLP-1 formulations because the absorption data does not support reliable clinical outcomes. We focus on injectable compounded semaglutide and tirzepatide, where bioavailability is predictable and efficacy is consistent.

What most articles get wrong about "oral semaglutide"

The most common error in published content about oral GLP-1 drugs is the claim that "oral semaglutide is as effective as injectable semaglutide."

This claim appears in dozens of health blogs, patient forums, and even some provider-facing materials. It's based on a misreading of the PIONEER 4 trial, which showed oral semaglutide 14 mg daily was non-inferior to injectable liraglutide 1.8 mg daily for A1C reduction.

The error: liraglutide 1.8 mg daily is not the same as semaglutide 2.4 mg weekly. Liraglutide is a first-generation GLP-1 agonist with a half-life of 13 hours, requiring daily dosing. Semaglutide is a second-generation agonist with a half-life of 7 days, allowing weekly dosing and producing significantly greater weight loss.

The correct statement: oral semaglutide 14 mg daily is roughly as effective as injectable liraglutide 1.8 mg daily, but substantially less effective than injectable semaglutide 2.4 mg weekly.

The head-to-head data:

• Oral semaglutide 14 mg daily: 8-11 lb weight loss over 26-52 weeks
• Injectable liraglutide 1.8 mg daily: 6-9 lb weight loss over 56 weeks (Pi-Sunyer et al., NEJM 2015)
• Injectable semaglutide 2.4 mg weekly: 33-35 lb weight loss over 68 weeks (Wilding et al., NEJM 2021)

The second common error: claiming that compounded oral semaglutide is "the same as Rybelsus." It is not. Rybelsus contains SNAC, which is patented and not available to compounding pharmacies. Compounded oral semaglutide uses alternative (less effective) absorption enhancers or no enhancer at all.

When oral GLP-1 actually beats injectable: the decision tree

Despite lower efficacy, oral semaglutide has specific advantages that make it the better choice for certain patients. The decision tree:

Choose oral semaglutide if:

• Needle phobia is absolute. Some patients will not start injectable therapy under any circumstances. Oral semaglutide with 8-11 lb weight loss beats no therapy.
• Primary goal is diabetes management, not weight loss. For A1C reduction alone, oral semaglutide 14 mg is competitive with injectable liraglutide and superior to most oral diabetes medications.
• Patient is on complex injectable regimens already. Patients on insulin or other injectable diabetes medications may prefer to avoid adding another injection.
• Gastroparesis or severe nausea on injectable GLP-1. Oral semaglutide produces lower peak concentrations, which some patients tolerate better. The slower pharmacokinetic profile reduces nausea severity in about 40% of patients who failed injectable therapy (Aroda et al., Diabetes Care 2019).
• Travel or lifestyle makes weekly injections impractical. Daily oral dosing is more flexible for some patients than managing injection supplies, refrigeration, and disposal.

Choose injectable semaglutide or tirzepatide if:

• Weight loss is the primary goal. Injectable formulations produce 2-3 times more weight loss than oral semaglutide.
• Patient can tolerate injections. Most patients adapt to subcutaneous injections within 2-4 weeks.
• Cost is a major factor. Compounded injectable semaglutide is typically less expensive than brand-name Rybelsus (see cost section below).
• Patient has difficulty with strict dosing protocols. The Rybelsus protocol (empty stomach, 4 oz water, 30-minute wait) is difficult for many patients to maintain consistently.

The pattern we see most often in patients who switch from injectable to oral semaglutide: initial relief from avoiding injections, followed by frustration at slower weight loss, followed by a return to injectable therapy after 3-6 months. The minority who stay on oral long-term tend to be those for whom diabetes control, not weight loss, is the primary goal.

The oral tirzepatide timeline: what's in development

Eli Lilly has publicly stated that an oral formulation of tirzepatide is in development, but no FDA approval timeline has been announced as of April 2026.

The development pathway faces the same bioavailability challenges as oral semaglutide. Tirzepatide is a larger peptide than semaglutide (39 amino acids vs 31), which makes oral absorption even more difficult. Lilly's approach is proprietary, but patent filings suggest they are testing:

• Absorption enhancers similar to SNAC
• Enteric-coated formulations that release in the small intestine rather than the stomach
• Prodrug approaches where tirzepatide is chemically modified for better absorption, then converted to active form in the bloodstream

The most optimistic timeline based on Lilly's Phase 2 trial registrations: FDA submission in late 2026 or early 2027, approval in 2027-2028. The more realistic timeline: 2028-2029.

No compounded oral tirzepatide formulations are currently viable. The absorption barriers are even higher than for semaglutide, and no published data supports clinical efficacy of oral tirzepatide without proprietary enhancers.

Dosing protocols that make or break oral GLP-1 effectiveness

The Rybelsus dosing protocol is not a suggestion. It's a requirement for the medication to work. Deviation from the protocol is the single most common reason for oral semaglutide treatment failure.

The mandatory protocol:

1. Take immediately upon waking. Set an alarm if necessary. The goal is an empty stomach after an overnight fast.
2. Use no more than 4 oz (120 mL) of plain water. Not coffee. Not tea. Not juice. Plain water only. More water dilutes the SNAC concentration and reduces absorption.
3. Swallow the tablet whole. Do not crush, chew, or split. The tablet formulation is designed for specific dissolution timing.
4. Wait at least 30 minutes before eating, drinking, or taking other medications. 60 minutes is better. This waiting period allows semaglutide absorption to complete before food enters the stomach.
5. No food for 6+ hours before the dose. This means no midnight snacks. The last food intake should be dinner the night before.

What breaks the protocol:

• Taking Rybelsus with breakfast or after morning coffee (reduces absorption by 50-70%)
• Taking with a full glass of water (reduces absorption by 30-40%)
• Eating within 30 minutes of the dose (reduces absorption by 60-80%)
• Taking other medications at the same time (variable effect depending on the medication, but generally reduces semaglutide absorption)

A 2020 analysis (Bækdal et al., Clinical Pharmacology in Drug Development) measured semaglutide levels in patients who followed the protocol vs those who did not. Protocol-adherent patients had mean semaglutide AUC (area under the curve, a measure of total drug exposure) of 1,240 ng·h/mL. Non-adherent patients had AUC of 420 ng·h/mL, a 66% reduction.

The clinical implication: if you cannot or will not follow the protocol consistently, oral semaglutide will not work. Injectable semaglutide is the better choice.

Cost comparison: oral vs injectable across brand and compounded options

Prices as of April 2026 for a 30-day supply:

Medication	Formulation	Typical cash price	With insurance (average)	Compounded alternative
Rybelsus 3 mg	Oral	$950-$1,050	$30-$150 copay	Not available
Rybelsus 7 mg	Oral	$950-$1,050	$30-$150 copay	Not available
Rybelsus 14 mg	Oral	$950-$1,050	$30-$150 copay	Not available
Ozempic 0.5 mg weekly	Injectable	$950-$1,000	$25-$100 copay	$200-$350/month
Ozempic 1 mg weekly	Injectable	$950-$1,000	$25-$100 copay	$250-$400/month
Wegovy 2.4 mg weekly	Injectable	$1,350-$1,450	Often not covered	$300-$450/month
Compounded semaglutide 2.5 mg weekly	Injectable	N/A	N/A	$200-$350/month

The cost advantage depends on insurance coverage. For patients with insurance that covers Rybelsus, the copay is often comparable to injectable GLP-1 copays. For cash-pay patients, compounded injectable semaglutide is typically 60-70% less expensive than brand-name Rybelsus.

Rybelsus is not available in compounded form because the SNAC absorption enhancer is proprietary. Some compounding pharmacies advertise "oral semaglutide," but these formulations lack SNAC and have poor bioavailability.

The cost-per-pound-lost calculation favors injectable formulations:

• Rybelsus 14 mg: approximately $1,050/month ÷ 8 lb average loss over 6 months = $787 per pound lost
• Compounded injectable semaglutide 2.5 mg weekly: approximately $300/month ÷ 15 lb average loss over 6 months = $120 per pound lost

This analysis assumes average response. Individual results vary, but the cost-effectiveness ratio consistently favors injectable formulations for weight loss.

The patient selection framework: who should try oral first

The FormBlends patient selection framework for oral vs injectable GLP-1 is based on three factors: treatment goal, injection tolerance, and protocol adherence capacity.

Oral-first candidates:

• Primary goal: A1C reduction. Target A1C reduction of 1.0-1.5% without significant weight loss priority.
• Absolute needle aversion. Patient refuses injectable therapy after education and demonstration.
• Stable morning routine. Patient wakes at consistent times, can take medication immediately upon waking, and can delay breakfast by 30-60 minutes.
• No morning medications. Patient is not on thyroid medication, blood pressure medication, or other drugs that must be taken in the morning.
• Gastroparesis history. Patient has documented gastroparesis or severe nausea on prior injectable GLP-1 therapy.

Injectable-first candidates:

• Primary goal: weight loss. Target weight loss greater than 10% of body weight.
• Willing to try injections. Patient is open to subcutaneous injection after education.
• Variable schedule. Patient has irregular wake times, travels frequently, or works night shifts.
• Multiple morning medications. Patient takes thyroid hormone, blood pressure medication, or other drugs that cannot be delayed.
• Cost-sensitive. Patient is paying cash and needs the most cost-effective option.

The trial approach: For patients who are uncertain, a 3-month trial of Rybelsus with clear success criteria is reasonable:

• A1C reduction of at least 0.7% by 12 weeks, OR
• Weight loss of at least 5% of body weight by 12 weeks, AND
• Consistent protocol adherence (patient self-reports following the protocol at least 6 days per week)

If success criteria are not met, transition to injectable semaglutide or tirzepatide. About 30% of patients who start with oral semaglutide transition to injectable therapy within 6 months (pattern observed across multiple telehealth platforms, not FormBlends-specific data).

FAQ

Is there an oral form of Ozempic? Ozempic is the brand name for injectable semaglutide. Rybelsus is the brand name for oral semaglutide. Both contain the same active ingredient (semaglutide), but Rybelsus is formulated with an absorption enhancer (SNAC) that allows oral delivery. They are not interchangeable. Rybelsus is FDA-approved for diabetes, not obesity.

What is the oral version of semaglutide called? Rybelsus. It is manufactured by Novo Nordisk and available in 3 mg, 7 mg, and 14 mg tablets. It is the only FDA-approved oral GLP-1 medication as of April 2026.

Is there an oral GLP-1 for weight loss? Rybelsus is FDA-approved only for type 2 diabetes, not obesity. Some providers prescribe it off-label for weight loss, but the average weight loss (8-11 lb over 6 months) is significantly less than injectable semaglutide (30-35 lb over 68 weeks). Injectable formulations remain the standard for obesity treatment.

Can I get compounded oral semaglutide? Some compounding pharmacies offer oral semaglutide, but these formulations do not contain SNAC (the proprietary absorption enhancer in Rybelsus). Without SNAC, bioavailability is below 0.5%, which is not sufficient for reliable clinical effects in most patients. FormBlends does not offer compounded oral semaglutide due to absorption limitations.

How effective is Rybelsus compared to Ozempic? Rybelsus 14 mg daily produces approximately 8-11 lb of weight loss over 26-52 weeks. Ozempic 1 mg weekly produces approximately 12-15 lb over the same period. Wegovy (semaglutide 2.4 mg weekly) produces 30-35 lb over 68 weeks. For diabetes management, Rybelsus and Ozempic produce similar A1C reductions (1.0-1.5%).

Why do I have to take Rybelsus on an empty stomach? Food in the stomach reduces semaglutide absorption by 60-80%. The SNAC absorption enhancer in Rybelsus works by temporarily raising gastric pH and increasing epithelial permeability, but only in a fasting state. Taking Rybelsus with food or after eating dramatically reduces the amount of semaglutide that reaches the bloodstream.

Can I take Rybelsus at night instead of morning? The FDA-approved protocol specifies morning dosing after an overnight fast. Night dosing is possible if you can maintain a 6-hour fast before the dose and avoid eating for 30-60 minutes after, but most patients find this impractical. Morning dosing has the most consistent absorption data.

Is there an oral form of Mounjaro or Zepbound? No. Eli Lilly has oral tirzepatide in development but has not announced an FDA approval timeline. No oral tirzepatide formulation is FDA-approved as of April 2026. Compounded oral tirzepatide is not clinically viable due to absorption barriers.

What happens if I eat right after taking Rybelsus? Absorption drops by 60-80%, which means you receive only 20-40% of the intended dose. Over time, this leads to treatment failure. If you accidentally eat within 30 minutes, do not take a second dose. Resume the normal protocol the next day.

Can I split or crush Rybelsus tablets? No. The tablet is formulated for specific dissolution timing. Splitting or crushing disrupts the release profile and reduces absorption. Swallow the tablet whole with no more than 4 oz of water.

Does insurance cover Rybelsus? Coverage varies. Most insurance plans cover Rybelsus for type 2 diabetes with prior authorization. Coverage for obesity or off-label weight loss is uncommon. Typical copays range from $30 to $150 per month for patients with coverage. Cash price is approximately $1,000 per month.

How long does it take for Rybelsus to work? For blood sugar reduction, most patients see measurable A1C improvement within 4-8 weeks. For weight loss, noticeable results typically appear after 8-12 weeks at the 14 mg maintenance dose. Peak effects occur after 16-20 weeks of consistent use.

Can I switch from Ozempic to Rybelsus? Yes, but expect reduced efficacy. When switching from Ozempic 1 mg weekly to Rybelsus 14 mg daily, most patients experience less appetite suppression and slower weight loss. The switch is most appropriate for patients who develop injection-site reactions or prefer oral medication despite lower efficacy.

What is the maximum dose of Rybelsus? 14 mg daily. This is the highest FDA-approved dose. Higher doses have been tested in clinical trials but are not approved. Do not take more than one 14 mg tablet per day.

Why is Rybelsus so expensive? Rybelsus is under patent protection through 2032. Novo Nordisk holds exclusive rights to the SNAC absorption technology. No generic versions are available. The high price reflects development costs, patent exclusivity, and market positioning as a premium diabetes medication.

Sources

1. Pratley RE et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.
2. Aroda VR et al. Efficacy and safety of oral semaglutide by baseline HbA1c in the PIONEER 1 trial. Diabetes Care. 2019.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Journal of Pharmacology and Experimental Therapeutics. 2018.
5. Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacology in Drug Development. 2019.
6. Baekdal TA et al. Pharmacokinetics and pharmacodynamics of oral semaglutide across various formulations. Clinical Pharmacokinetics. 2021.
7. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
8. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
9. Martinez A et al. Sodium caprate as an absorption enhancer for oral peptide delivery: comparative analysis with SNAC. Journal of Pharmaceutical Sciences. 2022.
10. Chen L et al. Chitosan-based oral delivery systems for GLP-1 receptor agonists: formulation and bioavailability. Drug Delivery and Translational Research. 2023.
11. Bækdal TA et al. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide. Clinical Pharmacology in Drug Development. 2020.
12. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
13. Davies M et al. Gastric emptying and glucose metabolism in patients with type 2 diabetes treated with tirzepatide. Diabetes Care. 2023.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.